Immunopharmacology in Skin Cancer: Progress, Challenges, and Future Directions

  • 2,130

    Total views and downloads

About this Research Topic

Submission deadlines

  1. Manuscript Submission Deadline 19 May 2026

  2. This Research Topic is currently accepting articles.

Background

Skin cancer, including melanoma and non-melanoma, remains a major global health concern primarily due to its tendency to spread quickly and resistance to traditional treatments. Recent progress in targeted therapies have changed the prognosis for many patients. By taking aim at specific genetic and molecular features of skin cancer, these therapies have provided new hope and opened the door to more personalized treatment approaches.

Despite these advances, treating skin cancer is not straightforward. Drugs that target common mutations (BRAF and MEK inhibitors), have delivered benefits, and patients are living longer, some achieve lasting responses.

However, not all patients respond, and many eventually see their disease return. The main challenge is that cancer cells adapt; they find new ways to survive, either by bypassing the drug's effects or by changing the way they grow.

This Research Topic aims to gather studies that highlight innovation and progress in the field of targeted therapy for skin cancer. We encourage submissions on topics such as:

•Discoveries of new molecular targets across melanoma and non-melanoma skin cancers.
•Innovation in advanced therapeutics as nanomedicine for skin cancers.
•Combination therapies, such as pairing targeted drugs with immunotherapy or other treatment types to overcome drug resistance mechanisms)
•Identification and use of biomarkers that can help predict how a patient will respond to a specific targeted therapy.
•Early clinical studies and trials bringing promising new targeted therapies closer to routine use.
•Detailed analysis of the safety and side-effect profiles of novel agents.

We are interested in Original Research, Review, Mini-review, and Perspective articles that cover the topics outlined above. Please note that case reports and case studies will not be considered for this Research Topic.

Studies on herbal medicines and Chinese TCM can be considered, but must fully comply with the Four Pillars of Best Practice (you can freely download the full version here ).

With this collection, we hope to provide a clear picture of skin cancer biology and advanced treatments, offering insights into both current progress and remaining challenges.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

  • Brief Research Report
  • Case Report
  • Clinical Trial
  • Data Report
  • Editorial
  • FAIR² Data
  • General Commentary
  • Hypothesis and Theory
  • Methods

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Keywords: immunopharmacology, melanoma, skin cancer, non melanoma skin cancer, non-melanoma skin cancer, targeted therapy, advanced therapeutics, nanomedicine, BRAF inhibitors, MEK inhibitors, drug resistance, combination therapy, immunotherapy, biomarkers, personalized medicine, molecular targets, precision oncology, clinical trials, novel agents, innovative treatments, skin cancer biology, cancer mutations, cancer genomics, therapeutic advances, patient outcomes, cancer prognosis, cancer adaptation, advanced drug delivery, translational research, safety profile, side effects, cancer survival, cancer recurrence, oncology innovation, molecular oncology, predictive biomarkers, cancer treatment breakthroughs, cancer therapy resistance, nanotechnology in cancer, immuno-oncology, molecular diagnosis, skin cancer management, future of skin cancer therapy, precision medicine in skin cancer, cancer cell adaptation, personalized treatment approaches, novel drug combinations, early clinical studies, new cancer therapeutics

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic editors

Topic coordinators

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Impact

  • 2,130Topic views
  • 96Article views
View impact